DE69635131D1 - Verwendung von beta-interferon zur behandlung der restenose - Google Patents

Verwendung von beta-interferon zur behandlung der restenose

Info

Publication number
DE69635131D1
DE69635131D1 DE69635131T DE69635131T DE69635131D1 DE 69635131 D1 DE69635131 D1 DE 69635131D1 DE 69635131 T DE69635131 T DE 69635131T DE 69635131 T DE69635131 T DE 69635131T DE 69635131 D1 DE69635131 D1 DE 69635131D1
Authority
DE
Germany
Prior art keywords
restenosis
treatment
beta interferon
beta
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69635131T
Other languages
English (en)
Other versions
DE69635131T2 (de
Inventor
Anthony Johns
J Mintzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berlex Laboratories Inc
Original Assignee
Berlex Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlex Laboratories Inc filed Critical Berlex Laboratories Inc
Application granted granted Critical
Publication of DE69635131D1 publication Critical patent/DE69635131D1/de
Publication of DE69635131T2 publication Critical patent/DE69635131T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69635131T 1995-11-30 1996-11-28 Verwendung von beta-interferon zur behandlung der restenose Expired - Lifetime DE69635131T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US565701 1990-08-13
US08/565,701 US5681558A (en) 1995-11-30 1995-11-30 Method of using beta-interferons to treat restenosis
PCT/IB1996/001468 WO1997019697A1 (en) 1995-11-30 1996-11-28 Method of using beta-interferons to treat restenosis

Publications (2)

Publication Number Publication Date
DE69635131D1 true DE69635131D1 (de) 2005-10-06
DE69635131T2 DE69635131T2 (de) 2006-07-06

Family

ID=24259751

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69635131T Expired - Lifetime DE69635131T2 (de) 1995-11-30 1996-11-28 Verwendung von beta-interferon zur behandlung der restenose

Country Status (11)

Country Link
US (1) US5681558A (de)
EP (1) EP0869813B1 (de)
JP (2) JP4116075B2 (de)
AT (1) ATE303158T1 (de)
AU (1) AU712960B2 (de)
CA (1) CA2238871C (de)
DE (1) DE69635131T2 (de)
DK (1) DK0869813T3 (de)
ES (1) ES2247607T3 (de)
WO (1) WO1997019697A1 (de)
ZA (1) ZA9610073B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866561A (en) * 1997-08-21 1999-02-02 Scimed Life Systems, Inc. Local delivery of estrogen for angiogenesis
US7018371B2 (en) * 2001-05-07 2006-03-28 Xoft, Inc. Combination ionizing radiation and radiosensitizer delivery devices and methods for inhibiting hyperplasia
US6537195B2 (en) 2001-05-07 2003-03-25 Xoft, Microtube, Inc. Combination x-ray radiation and drug delivery devices and methods for inhibiting hyperplasia
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
SE462364B (sv) * 1988-09-30 1990-06-18 Goeran Hansson Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos
JPH04116075A (ja) * 1990-09-03 1992-04-16 Hitachi Building Syst Eng & Service Co Ltd エレベータの乗り場報知装置
AU685080B2 (en) * 1993-01-07 1998-01-15 Thomas Jefferson University Antisense inhibition of C-MYC to modulate the proliferation of smooth muscle cells
US6780406B1 (en) * 1994-03-21 2004-08-24 The Regents Of The University Of Michigan Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene
CA2210622A1 (en) * 1995-11-17 1997-05-29 Toray Industries, Inc. An agent protecting endothelial cells

Also Published As

Publication number Publication date
DK0869813T3 (da) 2006-01-02
JP2008031179A (ja) 2008-02-14
DE69635131T2 (de) 2006-07-06
ZA9610073B (en) 1997-06-18
JP4116075B2 (ja) 2008-07-09
CA2238871A1 (en) 1997-06-05
EP0869813B1 (de) 2005-08-31
CA2238871C (en) 2006-08-15
ES2247607T3 (es) 2006-03-01
AU712960B2 (en) 1999-11-18
EP0869813A1 (de) 1998-10-14
US5681558A (en) 1997-10-28
WO1997019697A1 (en) 1997-06-05
AU1070397A (en) 1997-06-19
ATE303158T1 (de) 2005-09-15
EP0869813A4 (de) 2003-02-05
JP2000501093A (ja) 2000-02-02

Similar Documents

Publication Publication Date Title
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE76294T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
ES2155817T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
DE3687069D1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
ES2154253T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas.
DE69004081T2 (de) Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE69212620T2 (de) Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie
ES2082198T3 (es) Inhibidores de esteroide-sulfatasa.
DE69825440D1 (de) VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN
DE69331833D1 (de) Verwendung von vitamin d-glykosiden zur behandlung oder prävention von osteoporose
DE69004189D1 (de) Anordnungen zur behandlung menschlichen oder tierischen abfalls mittels mikrowellen.
DE69635131D1 (de) Verwendung von beta-interferon zur behandlung der restenose
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE59704933D1 (de) Verwendung von PHMB zur Behandlung von Tumorerkrankungen
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
DE3686019T2 (de) Die verwendung von nitrofurantoin zur behandlung und verhuetung von magen-darmkrankheiten.
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
DE68920757D1 (de) Lysyl-Oxidase-Inhibitoren.
ATE238795T1 (de) Verwendung von aminothiazolen zur wund- und hautbehandlung
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
DE69302250D1 (de) Verwendung von Isoquinolinon-Derivaten zur Behandlung von Hyperlipoproteinemia
DE69117566T2 (de) Verwendung von Isomonoolen zur Behandlung und Prophylaxe von Krebserkrankungen
ATE209910T1 (de) Verwendung von 6,7-substituierter 2- aminotetraline zur behandlung von zytokin- vermittleten entzündungszuständen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DF-MP, 80333 MUENCHEN